Immunosilencing a highly immunogenic protein trimerization domain.

Area of Science:

• Biotechnology
• Immunology
• Vaccine Development

Background:

• Therapeutic proteins and subunit vaccines often incorporate trimerization domains like the GCN4 isoleucine zipper (IZ) and T4 fibritin foldon (Fd).
• These domains can elicit potent immune responses against themselves, potentially affecting vaccine efficacy or therapeutic protein function.

Purpose of the Study:

• To investigate methods for dampening immune responses directed at heterologous trimerization domains in protein immunogens.
• To assess the efficacy of a glycan-shielded isoleucine zipper (IZN4) in reducing anti-IZ antibody responses.

Main Methods:

• Constructed an engineered isoleucine zipper domain (IZN4) featuring four N-linked glycosylation sites to shield the protein surface.
• Fused IZN4 to vaccine antigens, including HIV-1 envelope glycoprotein (Env) and influenza hemagglutinin (HA).
• Evaluated antibody responses against both the trimerization domain and the vaccine antigens in animal models.

Main Results:

• The IZN4 domain significantly reduced antibody responses against the IZ when fused to Env and HA immunogens.
• Antibody titers against the vaccine antigens (Env and HA) remained unaffected by the presence of IZN4.
• Glycan shielding effectively masked the immunogenic epitopes of the IZ domain.

Conclusions:

• Glycan shielding is a viable strategy to attenuate immune responses against immunogenic multimerization domains in protein-based therapeutics and vaccines.
• This approach allows for the use of trimerization domains for protein stabilization or assembly while minimizing unwanted immunogenicity.
• IZN4 offers a promising tool for enhancing the safety and efficacy of protein-based vaccines and therapeutics.